Table 3.
A | B | C | D | E | F | |
Progression to chronicity | +++ | ++ | +++ | ++ | ||
Histological inflammation | ++ | ++ | +++ | +++ | +/- | |
Histological fibrosis | + | + | ++ | ++ | +/- | |
Association with advanced liver disease | + | ++ | +++ | ++ | +/- | |
Association with HCC | + (subgeno A1) | + | ++ | ++ | ++ (subgeno F2) | |
Early HBeAg seroconversion | ++ | +++ | + | +++ | +++ | |
Sustained remission after HBeAg Seroconversion | +++ | +++ | ++ | ++ | ++ | |
HBsAg clearance | +++ | ++ | + | ++ | ||
Response to IFN Tx | +++ | ++ | + | +/- | + | +++ |
Association with PreCore mutations | - | ++ | + | +++ | ++ | +++ (F1 but not F2) |
Association with BCP mutation | ++ | ++ | ++ |
+/-: Possible association; - : No association; +: Slight association; ++: Moderate association; +++: Strong association. HBeAg: Hepatitis B e antigen; BCP; Basal core promotor; HCC: Hepatocellular carcinoma; IFN: Interferon.